Results 91 to 100 of about 4,367 (184)

Risankizumab [PDF]

Reactions Weekly, 2021
openaire   +2 more sources

Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia

Journal of Dermatological Treatment
Background Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in
Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel   +9 more
doaj   +1 more source

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open
Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).Methods This post
Filip van den Bosch, Laure Gossec, Frank Behrens, Ricardo Blanco, Laura C Coates, Michael Chen, Linyu Shi, Alexis Ogdie, Roberto Ranza, Ralph Lippe, Ahmed M Soliman, Yael Klionsky, Derek Coombs, Jamie R Urbanik, Thomas Iyile   +14 more
doaj   +1 more source

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study

Journal of Dermatological Treatment
Objectives Plaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life.
Margarida Contente, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres   +12 more
doaj   +1 more source

Clinical insights into IL-23 inhibition: risankizumab for Crohn’s disease through a systematic review and meta-analysis of randomized controlled trials

Therapeutic Advances in Gastroenterology
Background and aims: Crohn’s disease is a chronic inflammatory disorder with rising global prevalence, marked by abdominal pain, diarrhea, and fatigue.
Po-Feng Huang, Tien-Yu Huang, Yi-Chiao Cheng, Peng-Jen Chen, Wei-Kuo Chang, Chao-Feng Chang   +5 more
doaj   +1 more source

PO:05:069 | Risankizumab efficacy in peripheral and axial involvement: monocentric experience

Reumatismo
Risankizumab, an anti–IL-23 monoclonal antibody, is approved for the treatment of peripheral psoriatic arthritis (PsA), and increasing evidence suggests its potential efficacy in patients with concurrent axial involvement.
Società Italiana di Reumatologia
doaj  

Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA)

Dermatology and Therapy
Introduction Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients’ quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and ...
Mohammed Ibrahim Fatani, Abdulaziz Madani, Fahad Alzuriqan, Abdullah Albadri, Ahmed Aljedai, Hajer Almudaiheem, Maysa Tariq Eshmawi   +6 more
doaj   +1 more source

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study

Dermatology and Therapy
Introduction Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and
Federico Diotallevi, Giulia Matacchione, Anna Campanati, Elena Marinelli Busilacchi, Nadia Viola, Ilaria Pace, Beatrice Fontana, Roberta Roncarati, Massimiliano Bonafè, Manuela Ferracin, Jacopo Sabbatinelli, Fabiola Olivieri   +11 more
doaj   +1 more source

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

Meeting abstract du "19th Congress of ECCO", Stockholm, Suède, 21-24 février, 2024International audienceBackground Risankizumab is approved for moderate to severe Crohn’s disease (CD).
Roblin, X., Vuitton, L., Gilletta de Saint-Joseph, C., Nancey, S., Abitbol, V., Defrance, A., Paupard, T., Le Berre, C., Geyl, S., Nachury, M., Peyrin-Biroulet, L., Vidon, M., Fumery, M., Altwegg, R., Simon, M., Guillo, L., Biron, A., Duveau, N., Meyer, A., Stefanescu, C., Kirchgesner, J., Uzzan, M, Caillo, L., Buisson, A., Hébuterne, X., Laharie, D., Caron, B., Ah Soune, P.   +27 more
core   +1 more source

Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn’s Disease: A Real-World Retrospective Cohort Study from Taiwan

Journal of Inflammation Research
Ming-Jung Meng,1– 6 Shih-Hua Lin,8 Chien-Ming Chen,3,5,9 Tai-Di Chen,3,7,10 Chia-Jung Kuo,1– 5 Tony Kou,1,3,5 Cheng-Tang Chiu,1– 5 Puo-Hsien Le1– 61Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2Taiwan ...
Meng MJ, Lin SH, Chen CM, Chen TD, Kuo CJ, Kou T, Chiu CT, Le PH   +7 more
doaj